Form 8-K - Current report:
SEC Accession No. 0001193125-24-178824
Filing Date
2024-07-15
Accepted
2024-07-15 07:01:29
Documents
15
Period of Report
2024-07-11
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d723042d8k.htm   iXBRL 8-K 26474
2 EX-99.1 d723042dex991.htm EX-99.1 8467
6 GRAPHIC g723042logo.jpg GRAPHIC 7311
  Complete submission text file 0001193125-24-178824.txt   167317

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA beam-20240711.xsd EX-101.SCH 2836
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE beam-20240711_lab.xml EX-101.LAB 17236
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE beam-20240711_pre.xml EX-101.PRE 10803
17 EXTRACTED XBRL INSTANCE DOCUMENT d723042d8k_htm.xml XML 3494
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 857-327-8775
Beam Therapeutics Inc. (Filer) CIK: 0001745999 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39208 | Film No.: 241115850
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)